文献速递临床试验与 GCP基础与转化研究

托珠单抗在急性心肌梗死伴中高危心源性休克风险患者中的研究(DOBERMANN-T):双盲、安慰剂对照、单中心、随机临床试验的研究方案

Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial.
PubMed 文献 · Trials · 2024-11-05

DOBERMANN-T是一项双盲、安慰剂对照、单中心随机临床试验,计划纳入100例未发生心源性休克、接受急诊PCI、ORBI风险评分≥10的急性心肌梗死成人患者,随机给予单次静脉托珠单抗280 mg或安慰剂。主要终点为48小时内血浆proBNP峰值,次要终点包括心脏磁共振评估的心肌挽救指数及炎症和心肌损伤标志物。

要点

  • 纳入标准:急性心梗、入院时无心源性休克、症状发作24小时内行PCI、ORBI风险评分≥10。
  • 干预:单次静脉托珠单抗280 mg vs 安慰剂(生理盐水),共100例受试者随机。
  • 主要终点:48小时内血浆proBNP峰值;次要终点:心脏磁共振心肌挽救指数及炎症/心肌损伤标志物。

主要发现

  • 主要终点为48小时内血浆proBNP峰值,在输注前及输注后12、24、36、48小时连续测量。
  • 次要终点包括入院后24-48小时及3个月随访时的心脏磁共振评估左心室受累区、最终梗死面积及衍生挽救指数。
  • 次要终点还包括炎症标志物(C反应蛋白和白细胞计数)及心肌损伤标志物(肌钙蛋白T和肌酸激酶MB)。

关键数值与推荐

  • 纳入标准:急性心梗成人患者,入院时无心源性休克,症状发作24小时内接受PCI,ORBI风险评分≥10。
  • 干预:单次静脉托珠单抗280 mg或安慰剂(生理盐水)。
  • 主要终点:48小时内血浆proBNP峰值;次要终点:心脏磁共振心肌挽救指数及炎症/心肌损伤标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammation and neurohormonal activation play a significant role in the adverse outcome seen in acute myocardial infarction (AMI) and the development of cardiogenic shock (CS), which is associated with a mortality rate up to 50%. Treatment with anti-inflammatory drugs such as tocilizumab, an interleukin-6 receptor antagonist, has been shown to reduce troponin release and reduce the myocardial infarct size in AMI patients and it may therefore have cardioprotective properties. METHODS: This is a double-blind, placebo-controlled, single-center randomized clinical trial, including adult AMI patients without CS at hospital arrival, undergoing percutaneous coronary intervention (PCI) within 24 h from symptom onset, and at intermediate to high risk of developing CS (ORBI risk score ≥ 10). A total of 100 participants will be randomized to receive a single intravenous dose of tocilizumab (280 mg) or placebo (normal saline). The primary outcome is peak plasma pro-B-type natriuretic peptide (proBNP) within 48 h, assessed using serial measurements at intervals: before infusion, 12, 24, 36, and 48 h after infusion. Secondary endpoints include the following: (1) cardiac magnetic resonance imaging (CMR) during 24-48 h after admission and at follow-up after 3 months with assessment of left ventricular area at risk, final infarct size, and the derived salvage index and (2) biochemical markers of inflammation (C-reactive protein and leukocyte counts) and cardiac injury (troponin T and creatinine kinase MB). DISCUSSION: Modulation of interleukin-6-mediated inflammation in patients with AMI, treated with acute PCI, and at intermediate to high risk of in-hospital CS may lead to increased hemodynamic stability and reduced left ventricular infarct size, which will be assessed using blood biomarkers with proBNP as the primary outcome and inflammatory markers, troponin T, and CMR with myocardial salvage index as the secondary endpoints. TRIAL REGISTRATION: Registered with the Regional Ethics Committee (H-21045751), EudraCT (2021-002028-19), ClinicalTrials.gov (NCT05350592). Study registration date: 2022-03-08, Universal Trial Number U1111-1277-8523.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kunkel JB, Holle SLD, Hassager C, et al. Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial. Trials. 2024. PMID: 39501388. doi:10.1186/s13063-024-08573-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。